1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Chronic Lymphocytic Leukaemia: KOL Insight 2017

Chronic Lymphocytic Leukaemia: KOL Insight 2017

  • August 2017
  • ID: 5175288
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Will novel targeted therapies establish a place in CLL treatment pathways?

Chemo-immunotherapy regimens incorporating Rituxan/MabThera have traditionally been at the forefront of CLL treatment. How is this all set to change within the next few years? With Imbruvica and Venclexta/Venclyxto on the market, how do key opinion leaders (KOLs) see uptake of these treatments shaping up? Will targeted therapy combinations be able to match the efficacy of conventional regimens and become the new standards of care? Novel drugs acalabrutinib and umbralisib (TGR-1202) are also in the pipeline but what are the most important factors to ensure utilisation of these novel agents? Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Chronic Lymphocytic Leukaemia (CLL). Twelve US and European KOLs provide their candid insights on seven marketed products and five Phase III pipeline programmes.

Take a tour of the report now:

Methodology >
Research Objectives >
Questions Asked >
See the CLL therapies covered >
Find out who the 6 US and 6 European KOLs are >
Sample Pages >

Top Takeaways

Chemo-immunotherapies have dominated front-line treatment in CLL, but how long is this likely to continue? Will Roche’s anti-CD20 franchise, including Rituxan/MabThera and Gazyva/Gazyvaro, preserve their market share in a competitive landscape shifting towards oral targeted drugs?
How will Imbruvica’s role evolve in treatment of CLL? Following expanded approval of Janssen/AbbVie’s Imbruvica to first-line treatment, and publication of long-term efficacy data, how is the drug matching up to conventional regimens so far?
Is Venclexta/Venclyxto likely to become a key player? Find out how KOLs are prescribing this drug following its 2016 approval in CLL, how it compares to Imbruvica and Gilead’s Zydelig, and if can compete with these agents in the long-term?
How do KOLs feel about the extrapolated approval of rituximab biosimilars from non-Hodgkin lymphoma (NHL) to CLL? Will rituximab biosimilars be used in the treatment of CLL, and will cost be the key driver of uptake? Or will availability of subcutaneous Rituxan/MabThera limit adoption of rituximab biosimilars altogether?
Can acalabrutinib forge a niche in the treatment algorithm? Find out if KOLs think Acerta/AstraZeneca’s acalabrutinib is likely to gain approval in CLL, and whether the drug can compete with Imbruvica.
How do KOLs view PI3 kinase inhibitors as future treatments in CLL? Two PI3 kinase inhibitors are in the pipeline (Verastem’s duvelisib and TG Therapeutics’ umbralisib (TGR-1202), but which one are KOLs most excited about?
What other early-stage pipeline programmes are KOLS particularly excited about'Anti-CD19 CAR-T therapies have been game-changing in other haematologic malignancies but will the same hold true for CLL?
Are targeted drug combinations the future of CLL? Which combinations do KOLs think will be superior and will they be able to side-line chemotherapy regimens?

Quotes

“We will possibly get to cure CLL. There will be more combinations. The question is which is the best, the most affordable, and has least toxicity?” EU Key Opinion Leader

“In the next few years, it is very likely that chemotherapy will be completely replaced with targeted therapies.” US Key Opinion Leader

Marketed Therapies

Rituxan/MabThera (rituximab; Roche)
Gazyva/Gazyvaro (obinutuzumab; Roche)
Arzerra (ofatumumab; Novartis)
Imbruvica (ibrutinib; Janssen Biotech/AbbVie)
Zydelig (idelalisib; Gilead)
Venclexta/Venclyxto (venetoclax; AbbVie/Roche)
Truxima* (CT-P10; Celltrion/Teva/Mundipharma)
Rixathon/Riximyo* (GP2013; Sandoz/Novartis)


Pipeline Therapies

acalabrutinib (Acerta Pharmaceuticals/AstraZeneca)
duvelisib (Verastem)
umbralisib (TGR-1202; TG Therapeutics)
ublituximab (TG Therapeutics)
Revlimid (lenalidomide; Celgene)
PF-05280586* (Pfizer)
ABP 798* (Amgen)


KOLs Interviewed

KOLs from North America


Dr. Paul M. Barr, MD; Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Dr. Joshua Brody, MD; Assistant Professor of Hematology and Medical Oncology at the Mount Sinai Hospital, New York.
Dr. Bruce D. Cheson, MD, PhD; Professor of Medicine, Head of Hematology, and Director of Hematology Research at Lombardi at Georgetown University, Washington D.C.
Dr. Steven Coutre, MD; Professor of Medicine (Hematology) at the Stanford University Medical Center, Stanford University, California.
Dr. Ryan Jacobs, MD; Hematology and Oncology specialist at Carolinas Medical Center, Charlotte, North Carolina.
Dr. Nitin Jain, MD; Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

KOLs from Europe

Professor Christopher Fegan, MB, MD, FRCP, FRCPath; Consultant Haematologist and Director of the School of Medicine at Cardiff University, Wales, UK.
Dr. Francesco Forconi MD, DM, PhD, FRCPath; Associate Professor in Haematological Oncology, and Honorary Consultant in Haematology at the University of Southampton, UK.
Professor Paulo Ghia, MD, PhD; Associate Professor at the Università Vita-Salute San Raffaele and Head of the Unit of B-cell Neoplasia at the San Raffaele Scientific Institute at the San Raffaele Scientific Institute in Milan, Italy.
Dr. Marco Montillo, MD; Haematology Specialist at Department of Onco-Haematology, Division of Hematology, Niguarda Ca’ Granda Hospital, Milan, Italy.
Professor Olivier Tournihac, MD, PhD; Professor of Haematology at Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Anonymous, German KOL, MD, PhD; Associate Professor of Haematology at a leading German University.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage. 
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update. 
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report’s publication date. 
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date. 

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020, provides ...

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019SummaryHuman Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 9 molecules. Out of which approximately ...

Nephrotic Syndrome - Pipeline Review, H2 2019

Nephrotic Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Nephrotic Syndrome - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2019, provides an overview of the Nephrotic ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on